公开(公告)号：US20150023921A1

公开(公告)日：2015-01-22

申请号：US14244795

申请日：2014-04-03

Applicant: BIOTRON LIMITED

Inventor： Gary Dinneen EWART ,  Carolyn Anne LUSCOMBE ,  Michelle MILLER

IPC: C07C279/22 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/7056 ,  A61K31/166 ,  C07D333/24 ,  A61K31/381 ,  C07D231/12 ,  A61K31/415 ,  C07D307/54 ,  A61K31/341 ,  C07D213/69 ,  A61K31/4418 ,  A61K31/167 ,  A61K31/18 ,  C07C311/08 ,  A61K38/21

CPC classification number: C07C279/22 ,  A61K31/155 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61K31/4418 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07C311/08 ,  C07D213/69 ,  C07D231/12 ,  C07D307/54 ,  C07D333/24 ,  A61K2300/00

Abstract: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.

Abstract translation: 本发明涉及具有抗病毒活性的新型组合物，特别涉及对丙型肝炎病毒（HCV）有活性的协同组合物。 本发明还涉及用于延缓，减少或以其它方式抑制HCV生长和/或功能活性的方法。

公开(公告)号：US20250009713A1

公开(公告)日：2025-01-09

申请号：US18712518

申请日：2022-11-24

Applicant: BIOTRON LIMITED

Inventor： Michelle MILLER ,  Gary Dinneen EWART

IPC: A61K31/415 ,  A61P31/14

Abstract: The present invention relates to the treatment or prevention of SARS-COV-2 infection or COVID-19. In particular, the present invention relates to the use of N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of SARS-COV-2 infection or COVID-19.

公开(公告)号：US20170362170A1

公开(公告)日：2017-12-21

申请号：US15638362

申请日：2017-06-29

Applicant: BIOTRON LIMITED

Inventor： Gary Dinneen EWART ,  Carolyn Anne LUSCOMBE ,  Michelle MILLER

IPC: C07C279/22 ,  A61K31/155 ,  C07D231/12 ,  C07D213/69 ,  C07C311/08 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/7064 ,  A61K31/7056 ,  A61K31/4418 ,  A61K31/435 ,  A61K31/415 ,  A61K31/381 ,  A61K31/36 ,  A61K31/341 ,  A61K31/18 ,  A61K31/167 ,  A61K31/166 ,  C07D307/54 ,  C07D333/24

CPC classification number: C07C279/22 ,  A61K31/155 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61K31/4418 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07C311/08 ,  C07D213/69 ,  C07D231/12 ,  C07D307/54 ,  C07D333/24 ,  A61K2300/00

Abstract: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.